CCL25 and Familial prostate cancer: Recent studies have shown that CCL25/CCR9, via activating the PI3K/AKT signaling pathway, mediated anti-apoptotic processes in lung cancer [12], induced etoposide resistance in prostate cancer [14], and induced cis-platinum resistance, which is dependent on PI3K and not FAK, in breast and ovarian cancer [15, 16].